Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease

Biochemical and Biophysical Research Communications

Volumn 342, Issue 4, 2006, Pages 1034-1039

  Goldknopf, Ira L ^a   Sheta, Essam A ^a   Bryson, Jennifer ^a   Folsom, Brian ^a   Wilson, Chris ^a   Duty, Jeff ^a   Yen, Albert A ^b   Appel, Stanley H ^b  

^a Power3 Medical Products Inc   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Amytrophic lateral sclerosis; Complement; Immune; Inflammation; LC MS MS; Neurodegenerative; Parkinson's; Phosphorylation; Proteomic; Two dimensional electrophoresis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AMYLOID PROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3C1; COMPLEMENT COMPONENT C3C2A; COMPLEMENT COMPONENT C3C2B; COMPLEMENT COMPONENT C3DG; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BLOOD PROTEINS; COMPLEMENT C3C; HUMANS; PARKINSON DISEASE; RISK ASSESSMENT; RISK FACTORS;

EID: 33644903466     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.051     Document Type: Article

References (52)

1. L. Anderson, and N.G. Anderson High resolution two-dimensional electrophoresis of human plasma proteins Proc. Natl. Acad. Sci. USA 74 1977 5421 5425
2. I.L. Goldknopf, M.F. French, R. Musso, and H. Busch Presence of protein A24 in rat liver nucleosomes Proc. Natl. Acad. Sci. USA 74 1977 5492 5495
3. I.L. Goldknopf, C.W. Taylor, R.M. Baum, L.C. Yeoman, M.O. Olson, A.W. Prestayko, and H. Busch Isolation and characterization of protein A24, a "histone-like" non-histone chromosomal protein J. Biol. Chem. 250 1975 7182 7187
4. J. Klose Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals Human Genet. 26 1975 231 243
5. J. Margolis, and K.G. Kenrick 2-Dimensional resolution of plasma proteins by combination of polyacrylamide disc and gradient gel electrophoresis Nature 221 1969 1056 1057
6. P.Z. O'Farrell, H.M. Goodman, and P.H. O'Farrell High resolution two-dimensional electrophoresis of basic as well as acidic proteins Cell 12 1977 1133 1141
7. L.R. Orrick, M.O. Olson, and H. Busch Comparison of nucleolar proteins of normal rat liver and Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis Proc. Natl. Acad. Sci. USA 70 1973 1316 1320
8. S. Raymond Protein purification by elution convection electrophoresis Science 146 1964 406 407
9. R. Aebersold, and M. Mann Mass spectrometry-based proteomics Nature 422 2003 198 207
10. H. Kuruma, S. Egawa, M. Oh-Ishi, Y. Kodera, and T. Maeda Proteome analysis of prostate cancer Prostate Cancer Prostatic Dis. 8 2005 14 21
11. N.L. Anderson, and N.G. Anderson The human plasma proteome: history, character, and diagnostic prospects Mol. Cell. Proteomics 1 2002 845 867
12. V. Rachakonda, T.H. Pan, and W.D. Le Biomarkers of neurodegenerative disorders: how good are they? Cell Res. 14 2004 347 358
13. C.N. White, D.W. Chan, and Z. Zhang Bioinformatics strategies for proteomic profiling Clin. Biochem. 37 2004 636 641
14. S. Hanash HUPO initiatives relevant to clinical proteomics Mol. Cell. Proteomics 3 2004 298 301
15. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
16. W.D. Lee, and S.H. Appel Mutant genes responsible for Parkinson's disease Curr. Opin. Pharmacol. 4 2004 79 84
17. R.W. Orrell, J.J. Habgood, I. Gardiner, A.W. King, F.A. Bowe, R.A. Hallewell, S.L. Marklund, J. Greenwood, R.J. Lane, and J. deBelleroche Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis Neurology 48 1997 746 751
18. C.E. Shaw, Z.E. Enayat, B.A. Chioza, A. Al-Chalabi, A. Radunovic, J.F. Powell, and P.N. Leigh Mutations in all five exons of SOD-1 may cause ALS Ann. Neurol. 43 1998 390 394
19. T. Siddique, D.A. Figlewicz, M.A. Pericak-Vance, J.L. Haines, G. Rouleau, A.J. Jeffers, P. Sapp, W.Y. Hung, J. Bebout, and D. McKenna-Yasek Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity N. Engl. J. Med. 324 1991 1381 1384
20. M.D. Crispin, G.E. Ritchie, A.J. Critchley, B.P. Morgan, I.A. Wilson, R.A. Dwek, R.B. Sim, and P.M. Rudd Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure FEBS Lett. 566 2004 270 274
21. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Parkinsonism Relat. Disord. 10 Suppl. 1 2004 S3 S7
22. H. Rus, and F. Niculescu The complement system in central nervous system diseases Immunol. Res. 24 2001 79 86
23. P. Annunziata, and N. Volpi High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients Acta Neurol. Scand. 72 1985 61 64
24. T. Kawamata, H. Akiyama, T. Yamada, and P.L. McGeer Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue Am. J. Pathol. 140 1992 691 707
25. C. Schwab, J.C. Steele, and P.L. McGeer Neurofibrillary tangles of Guam Parkinson-dementia are associated with reactive microglia and complement proteins Brain Res. 707 1996 196 205
26. T. Yamada, P.L. McGeer, and E.G. McGeer Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins Acta Neuropathol. (Berlin) 84 1992 100 104
27. P.L. McGeer, H. Akiyama, S. Itagaki, and E.G. McGeer Activation of the classical complement pathway in brain tissue of Alzheimer patients Neurosci. Lett. 107 1989 341 346
28. E.J. Finehout, Z. Franck, and K.H. Lee Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease Dis. Markers 21 2005 93 101
29. J.S. Henkel, J.I. Engelhardt, L. Siklos, E.P. Simpson, S.H. Kim, T. Pan, J.C. Goodman, T. Siddique, D.R. Beers, and S.H. Appel Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue Ann. Neurol. 55 2 2004 221 235
30. J.S. Henkel, D.R. Beers, L. Siklos, S.H. Appel, The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS, Mol. Cell Neurosci. 2005, In press.
31. W. Le, D. Rowe, W. Xie, I. Ortiz, Y. He, and S.H. Appel Microglial activation and dopaminergic cell injury: and in vitro model relevant to Parkinson's disease J. Neurosci. 21 2001 8447 8455
32. Y. He, W.D. Le, and S.H. Appel Role of Fcgamma receptors in nigral cell injury induced by Parkinson's disease immunoglobulin injection into mouse substantia nigra Exp. Neurol. 176 2002 322 327
33. E.P. Simpson, Y.K. Henry, J.S. Henkel, R.G. Smith, and S.H. Appel Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden Neurology 62 2004 1758 1765
34. P.O. Forsberg, S.C. Martin, B. Nilsson, P. Ekman, U.R. Nilsson, and L. Engstrom In vitro phosphorylation of human complement factor C3 by protein kinase A and protein kinase C. Effects on the classical and alternative pathways J. Biol. Chem. 265 1990 2941 2946
35. K.N. Ekdahl, and B. Nilsson Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b J. Immunol. 154 1995 6502 6510
36. K. Nilsson Ekdahl, and B. Nilsson Phosphorylation of complement component C3 after synthesis in U937 cells by a putative protein kinase, casein kinase 2, which is regulated by CD11b: evidence that membrane-bound proteases preferentially cleave phosphorylated C3 Biochem. J. 328 Pt. 2 1997 625 633
37. C.F. Orr, D.B. Rowe, Y. Mizuno, H. Mori, and G.M. Halliday A possible role for humoral immunity in the pathogenesis of Parkinson's disease Brain 128 2005 2665 2674
38. D.E. Hourcade, L. Mitchell, L.A. Kuttner-Kondo, J.P. Atkinson, and M.E. Medof Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb J. Biol. Chem. 277 2002 1107 1112
39. D.E. Isenman, E.R. Podack, and N.R. Cooper The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase J. Immunol. 124 1980 326 331
40. M.K. Pangburn, and H.J. Muller-Eberhard Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells Proc. Natl. Acad. Sci. USA 75 1978 2416 2420
41. M.K. Pangburn, R.D. Schreiber, and H.J. Muller-Eberhard Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution J. Exp. Med. 146 1977 257 270
42. J.M. Weiler, M.R. Daha, K.F. Austen, and D.T. Fearon Control of the amplification convertase of complement by the plasma protein beta1H Proc. Natl. Acad. Sci. USA 73 1976 3268 3272
43. G.A. Tennent, L.B. Lovat, and M.B. Pepys Serum amyloid P component prevents peoteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis Proc. Natl. Acad. Sci. USA 92 1995 4299 4303
44. S.M. Lippa, C.F. Lippa, and H. Mori Alpha-synuclein aggregation in pathological aging and Alzheimer's disease: the impact pf beta-amyloid plaque level Am. J. Alzheimers Dis. Other Demen. 20 2005 315 318
45. O. Pletnikova, N. West, M.K. Lee, G.L. Rudow, R.L. Skolasty, T.M. Dawson, L. Marsh, and J.C. Troncoso Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases Neurobiol. Aging 26 2004 1183 1192
46. H. Yagi, E. Kusaka, H. Kunihiro, T. Mizobata, and Y. Kawata Amyloid fibril formation of a-synuclein is accelerated by amyloid seeds of other proteins J. Biol. Chem. 280 2005 38609 38616
47. P.G. de Frutos, Y. Hardig, and B. Dahlback Serum amyloid P component binding to C4b-binding protein J. Biol. Chem. 45 1995 26950 26955
48. C. Schwab, J.C. Steele, E.G. McGeer, and P.L. McGeer Amyloid P immunoreactivity precedes C4d deposition on extracellular neurofibrillary tangles Acta Neuropathol. (Berlin) 93 1997 87 92
49. R. Veerhuis, I. Janssen, C.J. De Groot, F.L. Van Muiswinkel, C.E. Hack, and P. Eikelenboom Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor Exp. Neurol. 160 1999 289 299
50. R. Veerhuis, M.J. Van Breemen, J.M. Hoozemans, M. Morbin, J. Ouladhadj, F. Tagliavini, and P. Eikelenboom Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro Acta Neuropathol. (Berlin) 105 2003 135 144
51. S. Ranganathan, E. Williams, P. Ganchev, V. Gopalakrishnan, D. Lacomis, L. Urbinelli, K. Newhall, M.E. Cudkowicz, R.H. Brown Jr., and R. Bowser Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis J. Neurochem. 95 2005 1461 1471
52. M.E. Alexianu, M. Kozovska, and S.H. Appel Immune reactivity in a mouse model of familial ALS correlates with disease progression Neurology 57 2001 1282 1289